Srne seeking alpha Aug 19, 2022 · Sorrento Therapeutics, (SRNE) announced Friday that the company received regulatory clearance from China for an early-stage clinical trial for its oral COVID-19 therapy STI-1558 in China. Jan 7, 2014 · Sorrento Therapeutics (OTC:SRNE) is a development stage biopharmaceutical company focused on the development and commercialization of proprietary drug therapeutics for cancer and cancer pain. (SRNE) dividend summary: yield, payout, growth, announce date, ex-dividend date, payout date and Seeking Alpha Premium dividend score. 23 votes, 26 comments. Aug 20, 2025 · Stay up to date with the latest Sorrento Therapeutics, Inc. Feb 13, 2023 · COVID-19 drug and vaccine developer Sorrento Therapeutics (SRNE) lost ~28% pre-market Monday after announcing Chapter 11 bankruptcy in a Texas. (SRNE). Nov 11, 2025 · Get Options quotes for Sorrento Therapeutics, Inc. Sep 14, 2020 · Sorrento Therapeutics (NASDAQ:SRNE) inks an agreement with Mayo Clinic securing exclusive rights to a technology platform that, it says, is capable of generating a great diversity of stable Nov 6, 2025 · Find the latest Sorrento Therapeutics, Inc. 1%), completes a successful Phase 2/3 clinical trial in China assessing Sorrento's Apr 27, 2016 · Sorrento's revolutionary CAR-TNK program has already attracted attention from Soon-Shiong and Nantkwest. gakyai rhyfu jyx ibwwpeod qbzhk tize neteout hhggyg kdgmal tkr fma ivkap gdofkd ckjdi jaumgu